Table 1.
Demographic and clinical characteristics of patients with prostate cancer and the general population
| No. (%) |
|||||
|---|---|---|---|---|---|
| Prostate cancer(n = 18 134) | General population(n = 73 470) | P for χ2 | |||
| Ethnicity | <.001 | ||||
| Hispanic | 1588 | (8.8) | 5032 | (6.9) | |
| Non-Hispanic | 16 546 | (91.2) | 68 438 | (93.2) | |
| Race | <.001 | ||||
| Asian | 106 | (0.6) | 559 | (0.8) | |
| Black | 130 | (0.7) | 220 | (0.3) | |
| Multiple races | 625 | (3.5) | 2133 | (2.9) | |
| Othera | 19 | (0.1) | 309 | (0.4) | |
| Missing | 112 | (0.6) | 1443 | (2.0) | |
| Baseline body mass indexb | <.001 | ||||
| <18.5 | 41 | (0.2) | 233 | (0.3) | |
| 18.5-24.9 | 4183 | (23.1) | 3210 | (23.7) | |
| 25.0-29.9 | 8704 | (48.0) | 17421 | (46.2) | |
| ≥30 | 4166 | (23.0) | 33904 | (25.5) | |
| Missing | 1040 | (5.7) | 18 702 | (4.4) | |
| Baseline Charlson Comorbidity Index | .003 | ||||
| 0 | 9283 | (51.2) | 36 898 | (50.2) | |
| ≥1 | 8851 | (48.8) | 36 572 | (49.8) | |
| Educationb | .001 | ||||
| High school or less | 8217 | (45.3) | 34 224 | (46.6) | |
| College | 5039 | (27.8) | 19 418 | (26.4) | |
| Post-college | 4878 | (26.9) | 19 828 | (27.0) | |
| Baseline marital status | .004 | ||||
| Married | 16 012 | (88.3) | 65 071 | (88.6) | |
| Widowed | 1368 | (7.5) | 5102 | (6.9) | |
| Unmarriedc | 754 | (4.2) | 3297 | (4.5) | |
| Baseline health insurance status | <.001 | ||||
| Medicare | 6793 | (37.5) | 22 462 | (30.6) | |
| Other government supportd | 381 | (2.1) | 1624 | (2.2) | |
| Private health insurance | 6782 | (37.4) | 27 840 | (37.9) | |
| Blue Cross/Blue Shield | 1584 | (8.7) | 6015 | (8.2) | |
| Othere | 597 | (3.3) | 3699 | (5.0) | |
| Missing | 1997 | (11.0) | 11 830 | (16.1) | |
| No. (%) |
|
|---|---|
| Prostate cancer | |
| (n = 18 134) | |
| Residency | |
| Urban | 15 391 (84.9) |
| Rural | 2743 (15.1) |
| US Census Bureau tract-level median household income | |
| ≤$32 047 | 444 (2.5) |
| $32 048-$53 412 | 6053 (33.4) |
| $53 413-$106 826 | 11 035 (60.9) |
| $106 827-$373 894 | 595 (3.3) |
| Missing | —f |
| Yost Socioeconomic Indexg | |
| Quintile 1 | 3094 (17.1) |
| Quintile 2 | 3330 (18.4) |
| Quintile 3 | 3643 (20.1) |
| Quintile 4 | 3394 (18.7) |
| Quintile 5 | 4531 (25.0) |
| Unknown | 143 (0.8) |
| Age at diagnosis, y | |
| <50 | 421 (2.3) |
| 50-59 | 3720 (20.5) |
| 60-69 | 7391 (40.8) |
| 70-79 | 5140 (28.3) |
| ≥80 | 1462 (8.1) |
| Follow-up time, median (IQR), y | 7.43 (3.79-10.39) |
| PSA at diagnosis, median (IQR), ng/mL | 6.6 (4.8-10.4) |
| PSA value, ng/mL | |
| <4.0 | 1875 (10.3) |
| 4.0-6.9 | 6570 (36.2) |
| 7.0-10.0 | 3167 (17.5) |
| 10.1-20.0 | 2454 (13.5) |
| >20.0 | 1691 (9.3) |
| Missing | 2377 (13.1) |
| Gleason Grade Grouph | |
| 3 + 3 or less | 7435 (41.0) |
| 3 + 4 | 5271 (29.1) |
| 4 + 3 | 2394 (13.2) |
| 4 + 4 | 1476 (8.1) |
| 9 or 10 | 1558 (8.6) |
| Modified risk groupi | |
| Very low | 1956 (10.8) |
| Low | 2977 (16.4) |
| Favorable intermediate | 5079 (28.0) |
| Unfavorable intermediate | 3225 (17.8) |
| High | 2293 (12.6) |
| Very high | 2604 (14.4) |
| American Joint Committee on Cancer staging | |
| I | 4933 (27.2) |
| II | 9095 (50.2) |
| III | 3174 (17.5) |
| IV | 932 (5.1) |
| First course of treatment | |
| Surgery only | 7137 (39.4) |
| Radiation only | 3510 (19.4) |
| Hormone only | 831 (4.6) |
| Surgery + other treatmentj | 501 (2.8) |
| Radiation + hormone | 1804 (10.0) |
| Chemotherapy + other treatmentk | 363 (2.0) |
| Conservative treatmentl | 3988 (22.0) |
Included American Indian, Alaska Native, Native Hawaiian, and Other Pacific Islander. IQR = interquartile range; PSA = prostate-specific antigen.
Variables were imputed for missing values.
Includes Never married, Unmarried, and Unmarried and both legal parents living together.
Includes Medicaid, Other government support, and Department of Corrections and Rehabilitation institutions.
Includes Out of pocket and Miscellaneous.
Cells with <11 were suppressed to protect patient identity.
The index is constructed using a factor analysis of 7 variables of socioeconomic status.
Variables were created based on imputed Gleason pattern and PSA value.
Defined by the National Comprehensive Cancer Network.
Includes the combination of surgery and androgen-deprivation therapy and surgery and radiation therapy.
Includes the combination of chemotherapy, surgery, and radiation therapy; surgery and chemotherapy; radiation therapy and chemotherapy; and radiation therapy, hormone therapy, and chemotherapy.
Includes active surveillance, watchful waiting, and no treatment.